Good news for shareholders of Anheuser-Busch Cos. (NYSE: BUD). Shares of the world's second-largest brewer are surging over 8% to $56.81 on a report that it may receive a bid worth $46 billion from InBev NV.
Just last week I moped about the lack of new developments in the reported talks between Anheuser-Busch and InBev, saying that as the industry is showing signs of consolidation, BUD seems a little lonely. Well, I may have spoken too soon considering today's reports.
According to Alphaville, the Financial Times' blog, InBev, the maker of Stella Artois, is working on a $46 billion bid, worth $65 a share, for Anheuser-Busch. The sources were not identified, but they indicated "that while extensive work had been carried out on the transaction, InBev was 'not about to push the button.'" There were no official comments.
If the deal is carried out, the second-largest shareholder, Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK.A), could stand to profit from its 5% stake. Buffett, profit? Nah! Barclay's, by the way, is the biggest stakeholder.
If the companies indeed join forces, they would cover the globe between them, pump out around 350 million hectolitres of beer and other beverages annually. Annual revenues would be around $20 billion and have a market capitalization close to $100 billion.
Since the first approach last October, InBev believes Mr Busch would be more willing to deal as pressure from shareholders have been increasing. And financing, you may ask, in this climate? Well, about $50 billion has been provisionally arranged with JPMorgan Chase & Co. and Banco Santander SA.
Now the question is, do we buy BUD shares at $57, hoping to cash in at $65?
Last updated: February 12, 2012: 03:26 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Some walnut growers want to stop selling to Diamond, Reuters says
- EASA orders Airbus A380s to be inspected, Der Spiegel says
- Sikorsky signs MOU with ASESA
- Lider Aviacao buys three Sikorsky S-92 helicopters
- Aviva won't be selling Taiwan JV stake, Reuters says
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?

